Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This pilot study examined the short-term impact of the classical ketogenic diet, a high-fat, very low-carbohydrate normocaloric diet, on gut microbiota composition. The classical ketogenic diet is used to treat drug-resistant epilepsy and Glucose Transporter 1 Deficiency Syndrome (GLUT1 DS). Researchers compared fecal microbiota composition before starting the diet and after three months on it. The motivation stemmed from animal studies showing that high-fat diets can substantially alter gut microbiota in ways that harm gut health.
Who was studied?
Six patients diagnosed with GLUT1 Deficiency Syndrome were enrolled and asked to provide fecal samples at two time points. Samples were collected once before starting the classical ketogenic diet and again after three months of adherence to the diet. The abstract does not report the ages, sex distribution, or other demographic details of these six patients. This was a small prospective observational pilot cohort rather than a large or randomized study population.
What were the most important findings?
Using RT-PCR, researchers quantified several bacterial groups, including Firmicutes, Bacteroidetes, Bifidobacterium spp., Lactobacillus spp., Clostridium perfringens, Enterobacteriaceae, Clostridium cluster XIV, Desulfovibrio spp., and Faecalibacterium prausnitzii. Firmicutes and Bacteroidetes levels showed no statistically significant change between baseline and the three-month follow-up. However, Desulfovibrio spp., a sulfate-reducing bacterial group, increased significantly after three months on the diet (p = 0.025). Desulfovibrio spp. is thought to be involved in worsening gut mucosal inflammation when associated with high consumption of animal-derived fats, linking this finding to sulfate-reducing bacteria and their metabolic byproducts such as hydrogen sulfide.
What are the greatest implications of this study?
The significant rise in Desulfovibrio spp. after a high-fat ketogenic diet raises concern that this dietary intervention could promote a bacterial group associated with gut mucosal inflammation, even over a short three-month period. Because the diet is normocaloric but very high in animal-derived fat, clinicians using it for GLUT1 DS or drug-resistant epilepsy should be aware of this potential shift in sulfate-reducing bacteria. The authors call for a future prospective study to further characterize changes in gut microbiota associated with the ketogenic diet. Given the small sample size of six patients, these findings should be viewed as preliminary signals warranting confirmation in larger cohorts.